AEON Biopharma (AEON) Competitors $0.56 -0.02 (-3.43%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends AEON vs. RLMD, ANVS, PYRGF, EPRX, GNLX, ACET, ME, ALLK, CASI, and FBLGShould you be buying AEON Biopharma stock or one of its competitors? The main competitors of AEON Biopharma include Relmada Therapeutics (RLMD), Annovis Bio (ANVS), PyroGenesis Canada (PYRGF), Eupraxia Pharmaceuticals (EPRX), Genelux (GNLX), Adicet Bio (ACET), 23andMe (ME), Allakos (ALLK), CASI Pharmaceuticals (CASI), and FibroBiologics (FBLG). These companies are all part of the "pharmaceutical preparations" industry. AEON Biopharma vs. Relmada Therapeutics Annovis Bio PyroGenesis Canada Eupraxia Pharmaceuticals Genelux Adicet Bio 23andMe Allakos CASI Pharmaceuticals FibroBiologics AEON Biopharma (NASDAQ:AEON) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Which has more volatility & risk, AEON or RLMD? AEON Biopharma has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500. Which has preferable valuation and earnings, AEON or RLMD? Relmada Therapeutics is trading at a lower price-to-earnings ratio than AEON Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAEON BiopharmaN/AN/A-$36.63M$0.183.13Relmada TherapeuticsN/AN/A-$98.79M-$2.87-0.99 Does the MarketBeat Community believe in AEON or RLMD? Relmada Therapeutics received 9 more outperform votes than AEON Biopharma when rated by MarketBeat users. However, 100.00% of users gave AEON Biopharma an outperform vote while only 41.46% of users gave Relmada Therapeutics an outperform vote. CompanyUnderperformOutperformAEON BiopharmaOutperform Votes8100.00% Underperform VotesNo VotesRelmada TherapeuticsOutperform Votes1741.46% Underperform Votes2458.54% Does the media prefer AEON or RLMD? In the previous week, Relmada Therapeutics had 2 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Relmada Therapeutics and 1 mentions for AEON Biopharma. AEON Biopharma's average media sentiment score of 3.00 beat Relmada Therapeutics' score of 0.00 indicating that AEON Biopharma is being referred to more favorably in the media. Company Overall Sentiment AEON Biopharma Very Positive Relmada Therapeutics Neutral Do analysts prefer AEON or RLMD? AEON Biopharma presently has a consensus target price of $5.00, suggesting a potential upside of 787.15%. Relmada Therapeutics has a consensus target price of $7.50, suggesting a potential upside of 163.16%. Given AEON Biopharma's stronger consensus rating and higher possible upside, research analysts clearly believe AEON Biopharma is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AEON Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Relmada Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is AEON or RLMD more profitable? AEON Biopharma's return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets AEON BiopharmaN/A N/A -994.63% Relmada Therapeutics N/A -129.80%-112.06% Do institutionals and insiders believe in AEON or RLMD? 22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 23.5% of AEON Biopharma shares are held by company insiders. Comparatively, 18.0% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryAEON Biopharma beats Relmada Therapeutics on 9 of the 14 factors compared between the two stocks. Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Get AEON Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for AEON and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AEON vs. The Competition Export to ExcelMetricAEON BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.69M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio3.135.5697.3414.18Price / SalesN/A348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book-0.697.885.805.12Net Income-$36.63M$153.61M$119.07M$225.99M7 Day Performance-7.62%-2.00%-1.83%-1.32%1 Month Performance-45.81%-7.47%-3.64%0.60%1 Year Performance-88.01%31.80%31.62%26.23% AEON Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AEONAEON Biopharma3.591 of 5 stars$0.56-3.4%$5.00+787.2%-88.5%$22.69MN/A3.135Positive NewsGap UpRLMDRelmada Therapeutics4.0741 of 5 stars$2.85-4.4%$7.50+163.2%-3.4%$89.92MN/A0.0010ANVSAnnovis Bio1.857 of 5 stars$6.51-2.5%$32.17+394.1%+8.1%$89.82MN/A-1.463PYRGFPyroGenesis CanadaN/A$0.49flatN/A+27.8%$89.52M$9.14M0.0090News CoverageGap UpEPRXEupraxia Pharmaceuticals2.4867 of 5 stars$3.62+11.0%$9.00+148.6%N/A$88.94MN/A0.0029Gap UpHigh Trading VolumeGNLXGenelux1.3298 of 5 stars$2.49+0.4%$18.25+632.9%-76.8%$85.65M$170,000.000.0010Gap UpACETAdicet Bio2.5176 of 5 stars$0.97-5.8%$7.50+675.5%-17.3%$84.87M$24.99M0.0090Analyst ForecastHigh Trading VolumeME23andMe1.1142 of 5 stars$3.15-8.2%$9.40+198.4%-82.6%$84.08M$219.64M0.00770ALLKAllakos4.3551 of 5 stars$0.94-6.9%$1.67+77.5%-50.8%$83.91MN/A-0.46131CASICASI Pharmaceuticals3.802 of 5 stars$5.22-2.2%$6.00+14.9%+0.4%$82.56M$33.88M0.00180FBLGFibroBiologics1.729 of 5 stars$2.24-5.9%$12.00+435.7%N/A$82.49MN/A0.0010 Related Companies and Tools Related Companies RLMD Alternatives ANVS Alternatives PYRGF Alternatives EPRX Alternatives GNLX Alternatives ACET Alternatives ME Alternatives ALLK Alternatives CASI Alternatives FBLG Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AEON) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AEON Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AEON Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AEON Stock Alerts